Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun:264-265:23-28.
doi: 10.1016/j.cancergen.2022.02.009. Epub 2022 Mar 6.

NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives

Victoria Casado-Medrano  1 , Alison O'Neill  1 , Stephen Halada  1 , Theodore W Laetsch  2 , Andrew J Bauer  1 , Aime T Franco  3
Affiliations
Review

NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives

Victoria Casado-Medrano et al. Cancer Genet. 2022 Jun.

Abstract

Pediatric and adult papillary thyroid cancer (PTC) share many similar oncogenic drivers, but differ in the pathological features and outcomes of the disease. The most frequent genetic alterations in adult PTCs are mutually exclusive point mutations in BRAF or the RAS family. In pediatric PTC, fusion oncogenes involving chromosomal translocations in tyrosine kinase (TK) receptors, most commonly RET and NTRK, are the most common genetic alterations observed. This review of the literature describes the current state of translational research in pediatric NTRK-driven thyroid cancer and highlights opportunities to improve our understanding and current models of pediatric PTC.

Keywords: Adult thyroid cancer; Mouse models; NTRK fusion; Oncogene; Pediatric.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
NTRK fusions identified in thyroid cancer. Trk fusion receptors lead to constitutive activation of signalling pathways such as Ras, phosphatidylinositol-3-kinase (PI3K) and phospholipase C (PLC)-y pathways
See this image and copyright information in PMC

References

    1. Kim P, Jia P, Zhao Z. Kinase impact assessment in the landscape of fusion genes that retain kinase domains: a pan-cancer study. Brief Bioinform. 2018;19(3):450–60. doi: 10.1093/bib/bbw127. - DOI - PMC - PubMed
    1. Santoro M, Moccia M, Federico G, Carlomagno F. RET Gene Fusions in Malignancies of the Thyroid and Other Tissues. Genes (Basel). 2020;11(4). doi: 10.3390/genes11040424. - DOI - PMC - PubMed
    1. Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019;30 Suppl 8:viii5–viii15. doi: 10.1093/annonc/mdz383. - DOI - PMC - PubMed
    1. Zhao X, Kotch C, Fox E, Surrey LF, Wertheim GB, Baloch ZW, Lin F, Pillai V, Luo M, Kreiger PA, Pogoriler JE, Linn RL, Russo PA, Santi M, Resnick AC, Storm PB, Hunger SP, Bauer AJ, Li MM. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome. JCO Precis Oncol. 2021;1. doi: 10.1200/PO.20.00250. - DOI - PMC - PubMed
    1. Franco AT, Ricarte-Filho JC, Isaza A, Jones Z, Jain N, Mostoufi-Moab S, Surrey L, Laetsch TW, Li MM, DeHart JC, Reichenberger E, Taylor D, Kazahaya K, Scott Adzick N, Bauer AJ. Fusion-oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers. bioRxiv. 2021:2021.07.23.453235. doi: 10.1101/2021.07.23.453235. - DOI - PMC - PubMed

Publication types

Substances